Arthritis, Juvenile Rheumatoid Clinical Trial
Official title:
Single Blinded RCT to Investigate the Clinical Effectiveness of Pre-formed Semi-rigid Foot Orthoses (FOs) on Pain, Quality of Life and Dynamic of Gait With Children Diagnosed With Juvenile Idiopathic Arthritis (JIA).
Modern modular foot-orthoses systems allow an integration of the cost and efficiency benefits afforded by the use of pre-formed semi-rigid FOs components, while simultaneously allowing a high degree of individualisation of prescription. Such systems, while popular, still remain unproven. Recent studies in paediatric rheumatology have made a contribution in developing guidelines with regards to pharmacological intervention in arthritic children. In addition, specific drug therapy protocols have been published to effectively help general practitioners, physiotherapists and ophthalmologists to successfully treat children with JIA patients (BSPAR 2006; Hull 2001; NICE guidelines 2002). A Cochrane systematic review on treatment of pes planus, highlighted that children with JIA were excluded as a group from most of the studies (Ashford et al. 2005). At present little evidence exists for the podiatric management of children affected by this disabling pathology, especially for orthotic management. This research has provided evidence to support the use of readily available off-the-shelf FOs in treating JIA children.
Introduction - Currently there is limited evidence supporting podiatric treatment of children
with JIA. The foot orthoses (FOs) prescribed to JIA children so far appeared to be very
expensive and required long time to manufacture before the fitting. This randomised
controlled trial (RCT) aimed to determine whether pre-formed FOs that can be prescribed at
chair side, impacted on pain, quality of life (primary outcomes) and/or gait-parameters
(secondary outcomes) in children affected by JIA.
Methods - The study took place at the Gait Analysis laboratory at Queen Margaret University -
Edinburgh and at the TORT Centre, Ninewells Hospital-Dundee. Children with JIA were diagnosed
according to the ILAR criteria. Intervention was blinded to the patients. The trial group
received Slimflex-plus FOs, with the addition of chair side corrections and the control FOs
supplied were made with leather board (1mm thick) only. Both FOs had the same black EVA top
cover. Primary outcomes were investigated using validated questionnaires (VAS, CHAQ and
PedsQL). Tekscan™ equipment (F-Scan™ and HR Walkway®) measured secondary outcomes in-shoe
pressure and force data with and without FOs intervention. Multiple foot strikes and
repetitive gait patterns were compared pre and post-treatment. Primary and secondary outcome
measures were recorded at baseline, 3rd and 6th month's period.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00807846 -
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
|
Phase 4 | |
Completed |
NCT00279747 -
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
|
Phase 3 | |
Completed |
NCT00652925 -
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
|
Phase 3 | |
Completed |
NCT00731965 -
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis
|
Phase 4 | |
Completed |
NCT02067962 -
Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing
|
N/A | |
Terminated |
NCT00868751 -
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
|
N/A | |
Terminated |
NCT00637780 -
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
|
Phase 4 | |
Completed |
NCT00001614 -
The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT01412021 -
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
|
||
Enrolling by invitation |
NCT02377245 -
Juvenile Inflammatory Rheumatism (JIR) Cohorte
|
||
Completed |
NCT00426218 -
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1/Phase 2 | |
Completed |
NCT00034853 -
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
|
Phase 3 | |
Completed |
NCT06000566 -
Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
|
||
Terminated |
NCT00511329 -
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
|
Phase 2/Phase 3 | |
Terminated |
NCT00688545 -
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
|
||
Recruiting |
NCT00012506 -
The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis
|
Phase 3 |